NRG Oncology RTOG 0625: A Randomized Phase II Trial of Bevacizumab with either Irinotecan or Dose-Dense Temozolomide in Recurrent Glioblastoma

BACKGROUND: Angiogenesis, a hallmark of glioblastoma, can potentially be targeted by inhibiting the VEGF pathway using bevacizumab, a humanized monoclonal antibody against VEGF-A. This study was designed to determine the efficacy and safety of these regimens in the cooperative group setting. METHODS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurooncol
Main Authors: Gilbert, Mark R., Pugh, Stephanie L, Aldape, Ken, Sorensen, A. Gregory, Mikkelsen, Tom, Penas-Prado, Marta, Bukshstein, Felix, Kwok, Young, Lee, R. Jeffrey, Mehta, Minesh
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5263144/
https://ncbi.nlm.nih.gov/pubmed/27770279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-016-2288-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados